Senseonics Holdings, Inc. is a medical technology company focused on the development and manufacturing of glucose monitoring products designed to transform lives in the diabetes community. Its glucose monitoring (CGM) systems Eversense 365 and Eversense E3 include a small sensor inserted completely under the skin that communicates with a smart transmitter worn over the sensor. Its CGM systems are indicated for continually measuring glucose levels for up to 365 days for Eversense 365 and 180 days for Eversense E3 in persons with diabetes age 18 and older. Eversense consists of three primary components: a small sensor inserted subcutaneously under the skin by a healthcare provider; an external removable smart transmitter that receives, assesses and relays data from the sensor and provides vibratory alerts; and a mobile app that receives data from the transmitter and provides real-time glucose readings, alerts and other data the person's mobile device.
Ticker SymbolSENS
Company nameSenseonics Holdings Inc
IPO dateMar 04, 2015
CEOGoodnow (Timothy T)
Number of employees117
Security typeOrdinary Share
Fiscal year-endMar 04
Address20451 Seneca Meadows Pkwy
CityGERMANTOWN
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code20876-7005
Phone13015157260
Websitehttps://www.senseonics.com/
Ticker SymbolSENS
IPO dateMar 04, 2015
CEOGoodnow (Timothy T)
A total of
0.00
USD has been distributed in dividends over the past 5 years.

No Data